By incorporating this prospective new-user design with active comparators, our study is better positioned to provide more reliable estimates regarding the effects of GLP-1 agonists on dementia relative to DPP-4 inhibitors and sulfonylureas.23 This evidence concerns the gene DPP4 and dementia.